Rousseau M.N., Vergne Laurence, Montes B., Peeters Martine, Reynes J., Delaporte Eric, Segondy M. (2001). Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 26 (1), p. 36-43. ISSN 1525-4135.
Titre du document
Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy
Année de publication
2001
Auteurs
Rousseau M.N., Vergne Laurence, Montes B., Peeters Martine, Reynes J., Delaporte Eric, Segondy M.
Source
Journal of Acquired Immune Deficiency Syndromes, 2001,
26 (1), p. 36-43 ISSN 1525-4135
Resistance-mutation patterns in the reverse transcriptase (RT) and protease genes of HIV-1 were analyzed in 22 patients who had been extensively pretreated and who failed to respond to highly active antiretroviral therapy (HAART). The number of mutations ranged from 8 to 19 (median, 13) : 4 to 12 (median, 6) mutations in the RT gene, and 4 to 8 (median, 7) mutations in the protease gene. In the RT gene, the most frequent resistance mutations were found at codons 215 (100%), 41 (95%), 67 (91%), and 210 (77%), 46 (50%), 36 (45%), and 84 (45%). Genotypic resistance to zidovudine, saquinavir, and indinavir was found in 100% of the patients. All patients showed also resistance or possible resistance to stavudine, abacavir, ritonavir, and nelfinavir. Mutations conferring genotypic resistance to nonnucleoside analogue RT inhibitors (NNRTIs) were found in 12 (80%) of the NNRTI-experienced patients and 1 of 7 NNRTI-naive patients. Our results from the multiplicity of RT and protease mutations that confer genotypic resistance to almost all available antiretroviral drugs. In these patients, genotypic resistance tests confirm the lack of alternative salvage therapy strategies based on the currently available antiretroviral drugs. (Résumé d'auteur)
Plan de classement
Maladies sexuellement transmissibles [052MALTRA03]
Descripteurs
SIDA ; MEDICAMENT ; RESISTANCE ; MUTATION ; METHODE D'ANALYSE ; TECHNIQUE PCR ; ENZYME ; GENE ; ETUDE EXPERIMENTALE ; ETUDE COMPARATIVE ; TRANSCRIPTASE REVERSE ; PROTEASE ; ZDV ; SAQUINAVIR ; INDINAVIR ; D4T ; ABACAVIR ; RITONAVIR ; NELFINAVIR ; AMPRENAVIR ; DDI ; DDC ; 3TC ; ABT-378
Localisation
Fonds IRD [F B010025197]
Identifiant IRD
fdi:010025197
